[Current Status and Future Direction of Cancer Genomic Medicine]

Area of Science:

• Oncology
• Genomics
• Precision Medicine

Background:

• Cancer gene panel testing has gained approval in Japan.
• Precision medicine approaches are being integrated into clinical practice.
• Clinical sequencing is poised to guide individual patient treatment decisions.

Purpose of the Study:

• To highlight the implementation of cancer gene panel testing in Japan.
• To discuss the role of genomic testing in precision oncology.
• To explore the utility of gene panels in identifying predictive biomarkers for immune-checkpoint inhibitor therapy.

Main Methods:

• Utilizing cancer gene panel testing for genomic profiling.
• Evaluating predictive biomarkers such as tumor mutation burden and PD-L1 IHC.
• Assessing MSI-testing as a companion diagnostic for immune-checkpoint inhibitors.

Main Results:

• Cancer gene panel testing is now approved and available in Japan.
• These tests are crucial for estimating key biomarkers like tumor mutation burden, PD-L1 IHC, and MSI status.
• Genomic testing facilitates personalized treatment strategies for cancer patients.

Conclusions:

• The approval of cancer gene panel testing in Japan marks a significant step towards implementing precision medicine.
• Genomic profiling through these panels is essential for treatment selection and biomarker assessment.
• These advancements in genomic testing are driving personalized cancer care in clinical settings.